12.2.2020

Finnish Patent and Registration Office Renders First Trademark Non-Use Revocation Decision

One of the main trademark principles is ‘use it or lose it’. This means that a trademark registration can be revoked if the owner has not put its mark to genuine use in the past five (5) years in connection with the goods and services the mark was registered for.

The new Finnish Trademark Act, which entered into force on 1 May 2019, introduced a brand new possibility to use a post-opposition administrative revocation procedure by filing a non-use action before the Finnish Patent and Registration Office.

The Office has now rendered its first trademark revocation decision in a case where our IP team successfully prosecuted the matter on behalf of a US client and the Office revoked the mark for non-use.

As applicants can now choose to file such actions before either the Finnish Market Court or the Office, here’s our take on the pros and cons when choosing the right forum.

Costs

The official fee for filing an application for revocation before the Office is EUR 400. If you decide to file such action before the Finnish Market Court, you need to pay official fee of EUR 2,050.

Even though the Office’s fee is much lower compared to the court’s fee, the downside is that the applicant cannot claim its own costs from the counterparty if the action is filed before the Office. In court proceedings, by contrast, the applicant can claim that the counterparty needs to pay both the applicant’s legal fees and the court’s official fee.

Length of the Proceedings

It is still too early to say which forum renders faster rulings. If the proprietor of a mark subject to non-use claim remains passive or admits the claim, no major difference exists when comparing the time it takes the Office or the Market Court to handle the case. However, if the owner of the mark resides outside Finland, the service of the non-use claim to the proprietor is far easier through the Office.

As regards actual proceedings, the Office is more willing to grant extensions to submit statements compared to the court. The office grants extensions of 2 months upon a simple request, and another 2 months with grounds. This usually leads to very long processing times if both parties file the maximum extension requests.

When looking at possibilities to appeal, the Office’s rulings can be appealed to the Market Court. If the applicant decides to file the action directly before the court, the appeal must be filed before the Supreme Court of Finland, which requires leave to appeal. Such leave is granted in approximately 7% of cases, which means that the Market Court’s ruling becomes final in most cases.

Conclusions

If it is more or less clear that the proprietor of the mark has not used its mark in the past five (5) years, it seems to be more efficient to file the claim before the Office. This applies especially if the proprietor of the mark resides outside Finland.

However, if the matter is more complex, requires witnesses to be heard or relates to a pending infringement case, it is likely better to file the claim to the Market Court.

Latest references

We advised Valio Oy in its acquisition of Raisio Oyj’s plant protein business, related fixed assets and the Härkis® and Beanit® fava bean brands. The fixed assets include, among other things, the production equipment of the factory that makes plant protein products in Kauhava. The transaction supports Valio’s strategy to grow from a dairy company to a food company. This business acquisition will make us an even more significant developer and producer of plant-based protein products. The demand for these products will grow in the long term, and a great deal of growth potential still remains. In 2022, we acquired the Gold&Green® business and, since then, we have been carrying out strong product development and renewed the brand. Following successful product launches, sales in the last quarter of 2024 increased by about 50% from the previous quarter. With this acquisition, we are building our own production capacity. The production equipment of the Kauhava factory is just right for our needs and situation. says Kimmo Luoma, Valio’s Senior Vice President. Valio is a Finnish dairy and food company founded in 1905 and owned by Finnish dairy cooperatives. Valio has subsidiaries in Sweden, Estonia, the United States and China. In 2023, the Group had a turnover of EUR 2 278 million and more than 4 000 employees.
Case published 14.2.2025
We successfully represented Arctic Biomaterials Oy before the Finnish Market Court in an extensive dispute concerning alleged patent infringement and invalidity of the patent-in-suit. Our client has invented next-generation bioabsorbable composites that are engineered with Arctic Biomaterials’ X3 bioactive natural mineral fibers, offering robust, bioactive reinforcement for orthopedic implants. These advanced composites empower customers to create high-strength bioabsorbable solutions for the most demanding applications. Back in 2019, Purac Biochem B.V. alleged, among other things, that our client’s Evolvecomp product had infringed Purac Biochem B.V.’s European patent validated in Finland protecting a biocompatible composite and its use. Purac Biochem B.V. filed a preliminary injunction against our client under the Act on Securing the Provision of Evidence in Civil Cases Concerning Industrial Property Rights and Copyright (344/2000). The Finnish Market Court issued an ex-parte injunction against our client on 2 April 2019 (MAO:150/19) and a final injunction on 19 February 2020 (MAO:59/20). Our client had disputed Purac Biochem B.V.’s patent infringement claim from the beginning and claimed that the patent-in-suit was invalid. After five years of litigation, the Finnish Market Court handed down a ruling in the joined invalidity and infringement cases on 10 October 2024 (MAO:560/2024 and MAO:561/2024) declaring Purac Biochem B.V.’s patent invalid and dismissing Purac’s infringement action against Arctic Biomaterials. Also, the preliminary injunction based on an alleged patent infringement imposed against Arctic Biomaterials was cancelled. The Market Court declared Purac Biochem B.V.’s patent invalid due to a lack of inventive step. The Market Court applied the could-would method for determining whether the patent-in-suit is inventive or not. The could-would method is based on determining whether a person skilled in the art would (not simply could, but would) have made a specific improvement to prior solutions, based on the available prior art. The Market Court ruled that it would have been obvious to a person skilled in the art to solve the objective technical problem of the patent-in-suit in the manner presented in claim 1, using as a starting point the closest prior art (prior patent publication) and combining it with the teaching of another prior art publication. The decision is final.
Case published 29.1.2025
We acted as Finnish counsel to Pernod Ricard in the sale of a portfolio of local Nordic brands to Oy Hartwall Ab, an affiliate of the Danish group Royal Unibrew. Pernod Ricard is a worldwide leader in the spirits and wine industry. The local portfolio of brands includes spirits, liqueurs and Finnish wine brands, the best-known being the liqueur Minttu, along with their related production assets based in Turku, Finland. The closing of the transaction remains subject to customary conditions.
Case published 21.10.2024
We are acting as the lead counsel to Fortum in a cross-border transaction in which Fortum is selling its recycling and waste business. The business is sold to thematic impact investing firm Summa Equity through its portfolio company NG Group. The debt-free purchase price is approximately EUR 800 million. The transaction is subject to authority approval and customary closing conditions. Fortum’s recycling and waste business to be sold comprises municipal and industrial waste management and end-to-end plastics, metals, ash, slag and hazardous waste treatment and recycling services. These businesses are located in Finland, Sweden, Denmark and Norway and currently employ approximately 900 employees.
Case published 18.7.2024